Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Interest Expense

Cost of servicing the company's debt during the period.

Pharvaris N.V.NASDAQ: PHVS

Interest Expense · Q3 FY2026 · quarter ended Sep 2026

Interest expense remains negative

Q3 FY2026 interest expense was €0, compared with €0 a year earlier. Trailing-twelve-month interest expense was €87.82K.

Context

  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near €0 or moves back toward the trailing-twelve-month quarterly average of €21.96K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
€0— QoQ
Last fiscal yearDec 2025
€0— YoY
LTMSep 2026
€87.82K— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

EUR · from the income statement

Latest · FY2025
0 EUR
Year-over-year change
—

Interest Expense vs competitors

How PHVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
PHVS Competitors
Interest Expense for PHVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$75.29M USD-20.2%-7.3%8.0%
PHARPharming Group N.V.LTM Mar 2026$12.95M USD+14.4%+58.4%3.5%
VERAVera Therapeutics, Inc.LTM Jun 2026$7.54M USD+0.8%+96.5%—
TVTXTravere Therapeutics, Inc.LTM Sep 2026$4.59M USD-59.3%-0.8%0.7%
PHVSPharvaris N.V.LTM Sep 2026€87.82K EUR———
RLYBRallybio CorporationLTM Mar 2026$0 USD——0.0%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$55.55B USD-519327.6%-12.0%5.4%
Peer median (excluding PHVS) —-20.2%-0.8%3.5%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.79M57.38M65.58M98.56M124.48M
Selling, General & Admin18.35M29.34M31.34M47.12M45.34M
Operating Expenses54.14M86.71M96.91M145.69M169.82M
Depreciation & Amortization77.37K152.94K257.55K269.56K418.35K
EBITDA(42.31M)(86.56M)(99.57M)(145.42M)(173.29M)
EBITDA Margin—————
Operating Income(54.14M)(86.71M)(96.91M)(145.69M)(169.82M)
Operating Margin—————
Interest Income2681605.47M0
Interest Expense278.18K16.11K000
Other Income / Expenses11.48M11.06M(2.91M)13.29M(3.89M)
Income Before Tax(42.66M)(75.65M)(99.83M)(132.4M)(173.71M)
Pre-Tax Margin—————
Income Tax Expense70.12K679.09K1.05M1.83M1.99M
Net Income(42.73M)(76.33M)(100.88M)(134.22M)(175.7M)
Net Margin—————
EPS (Basic)(1.41)(2.27)(2.63)(2.48)(2.97)
EPS (Diluted)(1.41)(2.27)(2.63)(2.48)(2.97)
Weighted Avg Shares30.41M33.59M38.39M54.02M59.16M
Weighted Avg Shares (Diluted)30.41M33.59M38.39M54.02M59.16M

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.